Find the next decision worth funding

Explore Opportunities

Most actionable first. Assess the next decision, not the size of the database.

20 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.

How “most actionable” works

Explicit ordinal order: all four gates PASS → concerns needing review → unresolved leads → fatal failures. Names and IDs break ties. UNKNOWN never counts as a pass. This is not an efficacy score or valuation. Private assumptions affect only your own results.

WATCH · APPROVED_FOR_MARKETING

Bulevirtide

Chronic Hepatitis Delta Virus Infection

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source

WATCH · ACTIVE_NOT_RECRUITING

Bulevirtide

Viral Hepatitis

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source

WATCH · ACTIVE_NOT_RECRUITING

Bulevirtide

Viral Hepatitis

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source

WATCH · RECRUITING

Bulevirtide

Chronic Hepatitis D

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source

WATCH · RECRUITING

Bulevirtide

HEPATITIS B CHRONIC, Hepatitis D, Periodontitis

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source

WATCH · COMPLETED

Bulevirtide (BLV)

Chronic Hepatitis D Infection

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source

WATCH · RECRUITING

Bulevirtide 2 mg and Brelovitug - 300 mg

Chronic Hepatitis D Infection

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source

WATCH · COMPLETED

Myrcludex B

Chronic Viral Hepatitis B With Delta-agent

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT No stopping reason reported; not proof of abandonment

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

No stopping reason reported; not proof of abandonment

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update UNKNOWN. Registry source